BioCentury | Dec 31, 2020
Regulation

119 drugs added to China’s reimbursement list, which includes more domestic PD-1s

...to reduce patient costs by about RMB28 billion ($4.3 billion) in 2021, according to the National Healthcare...
BioCentury | Dec 19, 2020
Product Development

Dec. 18 Quick Takes: FDA approves expanded label for Benlysta and first oral prostate cancer therapy; plus Novartis, FibroGen, A2i, China’s NRDL and more

...completed price negotiations Wednesday for inclusion of drugs in its updated National Drug Reimbursement List. The National Healthcare...
BioCentury | Nov 4, 2020
Politics, Policy & Law

China’s Hatch-Waxman Act: Not there yet

...and increasing use of VBP by the National Healthcare...
BioCentury | Oct 13, 2020
Product Development

$1B AMR Action Fund to assess first investments in 1Q21

...hospitals and help hospitals report antibiotic use and resistance data to the CDC and Prevention National Healthcare...
BioCentury | Aug 20, 2020
Politics, Policy & Law

Updated plan for China’s reimbursement increases pricing pressure on checkpoint inhibitors

...increase pricing pressure on eligible PD-1/PD-L1 inhibitors.The National Healthcare...
BioCentury | Aug 8, 2020
Regulation

China’s updated reimbursement list likely to see COVID-19 therapies, more anti-PD-1s

...updated to include countermeasures for COVID-19-associated respiratory disease as well as more PD-1/PD-L1 inhibitors. The National Healthcare...
BioCentury | May 1, 2020
Regulation

China's proposed annual NRDL revisions could increase pricing pressure

...Reimbursement List could increase pricing pressure for all included drugs. Draft opinions released by China’s National Healthcare...
BioCentury | Mar 26, 2020
Regulation

China’s NMPA suspends Abraxane imports after U.S. inspection

...the 46% of market share previously guaranteed to BeiGene under the centralized procurement program. China’s National Healthcare...
BioCentury | Feb 12, 2020
Politics, Policy & Law

When single-payer systems adopt innovation better than U.S. commercial payers

...covers them more narrowly. But it is also true that England will be the first national healthcare...
BioCentury | Sep 19, 2019
Translation in Brief

Public funding highlights

...Duke-NUS Medical School , Lee Kong Chian School of Medicine , Nanyang Technological University , National Healthcare...
Items per page:
1 - 10 of 31
BioCentury | Dec 31, 2020
Regulation

119 drugs added to China’s reimbursement list, which includes more domestic PD-1s

...to reduce patient costs by about RMB28 billion ($4.3 billion) in 2021, according to the National Healthcare...
BioCentury | Dec 19, 2020
Product Development

Dec. 18 Quick Takes: FDA approves expanded label for Benlysta and first oral prostate cancer therapy; plus Novartis, FibroGen, A2i, China’s NRDL and more

...completed price negotiations Wednesday for inclusion of drugs in its updated National Drug Reimbursement List. The National Healthcare...
BioCentury | Nov 4, 2020
Politics, Policy & Law

China’s Hatch-Waxman Act: Not there yet

...and increasing use of VBP by the National Healthcare...
BioCentury | Oct 13, 2020
Product Development

$1B AMR Action Fund to assess first investments in 1Q21

...hospitals and help hospitals report antibiotic use and resistance data to the CDC and Prevention National Healthcare...
BioCentury | Aug 20, 2020
Politics, Policy & Law

Updated plan for China’s reimbursement increases pricing pressure on checkpoint inhibitors

...increase pricing pressure on eligible PD-1/PD-L1 inhibitors.The National Healthcare...
BioCentury | Aug 8, 2020
Regulation

China’s updated reimbursement list likely to see COVID-19 therapies, more anti-PD-1s

...updated to include countermeasures for COVID-19-associated respiratory disease as well as more PD-1/PD-L1 inhibitors. The National Healthcare...
BioCentury | May 1, 2020
Regulation

China's proposed annual NRDL revisions could increase pricing pressure

...Reimbursement List could increase pricing pressure for all included drugs. Draft opinions released by China’s National Healthcare...
BioCentury | Mar 26, 2020
Regulation

China’s NMPA suspends Abraxane imports after U.S. inspection

...the 46% of market share previously guaranteed to BeiGene under the centralized procurement program. China’s National Healthcare...
BioCentury | Feb 12, 2020
Politics, Policy & Law

When single-payer systems adopt innovation better than U.S. commercial payers

...covers them more narrowly. But it is also true that England will be the first national healthcare...
BioCentury | Sep 19, 2019
Translation in Brief

Public funding highlights

...Duke-NUS Medical School , Lee Kong Chian School of Medicine , Nanyang Technological University , National Healthcare...
Items per page:
1 - 10 of 31